ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02797821
- Locations
- 🇩🇪
University of Würzburg, Würzburg, Germany
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Vanderbilt Medical Center Endocrinology, Nashville, Tennessee, United States
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT02763215
- Locations
- 🇬🇧
Clinical Trial Site, Guildford, United Kingdom
A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02618512
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02614898
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02605993
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02598583
- Locations
- 🇰🇷
Clinical Trial Site, Ulsan, Korea, Republic of
Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02531867
Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)
- Conditions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT02496689
- Locations
- 🇺🇸
Colorado Center for Bone Research, Lakewood, Colorado, United States
🇫🇷Hôpital Necker - Enfants Malades, Paris, France
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency
- Conditions
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT02376751
A Study to Identify and Characterize LAL-D Patients in High-risk Populations
Terminated
- Conditions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 640
- Registration Number
- NCT02345421
© Copyright 2024. All Rights Reserved by MedPath